
Arrowhead Pharmaceuticals Inc
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $28.555
- Today's High:
- $29.395
- Open Price:
- $29.13
- 52W Low:
- $23.09
- 52W High:
- $48.48
- Prev. Close:
- $29.24
- Volume:
- 739839
Company Statistics
- Market Cap.:
- $3.74 billion
- Book Value:
- 4.181
- Revenue TTM:
- $272.80 million
- Operating Margin TTM:
- -55.25%
- Gross Profit TTM:
- $243.23 million
- Profit Margin:
- -55.06%
- Return on Assets TTM:
- -11.81%
- Return on Equity TTM:
- -33.17%
Company Profile
Arrowhead Pharmaceuticals Inc had its IPO on 1993-06-16 under the ticker symbol ARWR.
The company operates in the Healthcare sector and Biotechnology industry. Arrowhead Pharmaceuticals Inc has a staff strength of 397 employees.
Stock update
Shares of Arrowhead Pharmaceuticals Inc opened at $29.13 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $28.56 - $29.4, and closed at $29.1.
This is a -0.48% slip from the previous day's closing price.
A total volume of 739,839 shares were traded at the close of the day’s session.
In the last one week, shares of Arrowhead Pharmaceuticals Inc have increased by +4.08%.
Arrowhead Pharmaceuticals Inc's Key Ratios
Arrowhead Pharmaceuticals Inc has a market cap of $3.74 billion, indicating a price to book ratio of 8.0438 and a price to sales ratio of 14.7115.
In the last 12-months Arrowhead Pharmaceuticals Inc’s revenue was $272.80 million with a gross profit of $243.23 million and an EBITDA of $-140096000. The EBITDA ratio measures Arrowhead Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Arrowhead Pharmaceuticals Inc’s operating margin was -55.25% while its return on assets stood at -11.81% with a return of equity of -33.17%.
In Q1, Arrowhead Pharmaceuticals Inc’s quarterly earnings growth was a positive 9.8% while revenue growth was a negative 3.6%.
Arrowhead Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 111.1111
- Trailing PE
- 0
- PEG
- -1.32
Its diluted EPS in the last 12-months stands at $-1.49 per share while it has a forward price to earnings multiple of 111.1111 and a PEG multiple of -1.32. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Arrowhead Pharmaceuticals Inc’s profitability.
Arrowhead Pharmaceuticals Inc stock is trading at a EV to sales ratio of 11.9672 and a EV to EBITDA ratio of -17.3173. Its price to sales ratio in the trailing 12-months stood at 14.7115.
Arrowhead Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $891.31 million
- Total Liabilities
- $87.15 million
- Operating Cash Flow
- $-36065000.00
- Capital Expenditure
- $27.31 million
- Dividend Payout Ratio
- 0%
Arrowhead Pharmaceuticals Inc ended 2025 with $891.31 million in total assets and $0 in total liabilities. Its intangible assets were valued at $891.31 million while shareholder equity stood at $446.77 million.
Arrowhead Pharmaceuticals Inc ended 2025 with $0 in deferred long-term liabilities, $87.15 million in other current liabilities, 199000.00 in common stock, $-813405000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $134.96 million and cash and short-term investments were $481.01 million. The company’s total short-term debt was $2,711,000 while long-term debt stood at $0.
Arrowhead Pharmaceuticals Inc’s total current assets stands at $574.81 million while long-term investments were $78.83 million and short-term investments were $346.05 million. Its net receivables were $69.43 million compared to accounts payable of $9.56 million and inventory worth $0.
In 2025, Arrowhead Pharmaceuticals Inc's operating cash flow was $-36065000.00 while its capital expenditure stood at $27.31 million.
Comparatively, Arrowhead Pharmaceuticals Inc paid $0 in dividends in 2025.
Other key metrics
- Current Trading Price
- $29.1
- 52-Week High
- $48.48
- 52-Week Low
- $23.09
- Analyst Target Price
- $61.93
Arrowhead Pharmaceuticals Inc stock is currently trading at $29.1 per share. It touched a 52-week high of $48.48 and a 52-week low of $48.48. Analysts tracking the stock have a 12-month average target price of $61.93.
Its 50-day moving average was $31.42 and 200-day moving average was $32.64 The short ratio stood at 4.5 indicating a short percent outstanding of 0%.
Around 492.1% of the company’s stock are held by insiders while 6870.1% are held by institutions.
Frequently Asked Questions About Arrowhead Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in phase 2b clinical trial for the treatment of dyslipidemia; ARO-HSD, which is completed phase 1/2 clinical trial to treat liver diseases; ARO-ENaC2, which is in pre-clinical stage for the treatment of dyslipidemia cystic fibrosis; ARO-C3 that is in phase 1/2a clinical trial to reduce production of complement component 3; ARO-DUX4, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH that is in phase 1 clinical trial to treat uncontrolled gout; ARO-COV, which is in pre-clinical stage for the treatment of COVID-19; ARO-RAGE, which is in phase 1/2a clinical trial to treat muco-obstructive or inflammatory pulmonary conditions; and ARO-MMP7 that is in phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop JNJ-75220795, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.